ERLOLIEVA 150MG TAB contains Erlotinib Tablets IP 150mg, a targeted oral anticancer medication manufactured by Allieva Pharma Private Limited and packed in bottles containing 30 tablets. Specifically designed for the treatment of EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and pancreatic cancer (combined with gemcitabine), ERLOLIEVA works as a tyrosine kinase inhibitor (TKI) that selectively blocks the epidermal growth factor receptor, thereby inhibiting tumor cell proliferation and survival. This oral tablet offers a convenient once-daily 150mg dosage taken on an empty stomach to maximize absorption and efficacy. Erlotinib is an advanced therapy option after failure of at least one prior chemotherapy regimen or as first-line treatment in EGFR mutation-positive NSCLC cases. It is produced in India and supplied by RADHAKRUSHNA MEDICALS with a minimum order quantity of 1 bottle. Erlotinib’s side effects include common reactions such as skin rash, diarrhea, fatigue, loss of appetite, and nausea, alongside rare but serious conditions like interstitial lung disease and severe skin reactions. Due to its potent nature, dose adjustments might be necessary depending on patient tolerance and liver function. ERLOLIEVA Tablets must be administered strictly under physician supervision and require a valid prescription for supply, ensuring safe and effective use in clinical oncology settings.

*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.